Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2017

01-10-2017 | Breast Oncology

Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel

Part 1: Definitions, Assessments, Education, and Future Directions

Authors: Sarah A. McLaughlin, MD, Alicia C. Staley, MBA, MS, BS, Frank Vicini, MD, FACR, FABS, Paul Thiruchelvam, BSc, MD, PhD, FRCS, Nancy A. Hutchison, MD, CLT-LANA, Jane Mendez, MD, Fiona MacNeill, FRCS, MD, FEBS, Stanley G. Rockson, MD, Sarah M. DeSnyder, MD, Suzanne Klimberg, MD, PhD, Michael Alatriste, LMT, CLT, Francesco Boccardo, MD, PhD, FACS, Mark L. Smith, MD, FACS, Sheldon M. Feldman, MD, FACS

Published in: Annals of Surgical Oncology | Issue 10/2017

Login to get access

Excerpt

Lymphedema is a chronic, debilitating disease defined as an abnormal, generalized, or regional accumulation of protein-rich interstitial fluid resulting in edema formation and change in tissue structure. Lymphedema reflects the “relative” imbalance between the rate of interstitial fluid generation (lymphatic load) and the degree to which the lymphatic vasculature (lymphatic transport capacity) is underdeveloped or damaged.1 …
Appendix
Available only for authorised users
Literature
1.
Rockson SG. Update on the biology and treatment of lymphedema. Curr Treat Options Cardiovasc Med. 2012;14:184–92.PubMedCrossRef
2.
Shih YC, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27:2007–14.PubMedCrossRef
3.
Basta MN, et al. Complicated breast cancer-related lymphedema: evaluating health care resource utilization and associated costs of management. Am J Surg. 2016;211:133–41.PubMedCrossRef
4.
5.
Ververs JM, et al. Risk, severity, and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer. 2001;37:991–9.PubMedCrossRef
6.
Shaitelman SF, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015;65:55–81.PubMedCrossRef
7.
The diagnosis and treatment of peripheral lymphedema: 2016 consensus document of the International Society of Lymphology. Lymphology. 2016;49:170–84.
8.
Armer JM, et al. Best Practice Guidelines in Assessment, Risk Reduction, Management, and Surveillance for Post-Breast Cancer Lymphedema. Curr Breast Cancer Rep. 2013;5:134–44.PubMedPubMedCentralCrossRef
9.
Ostby PL, et al. Surveillance recommendations in reducing risk of and optimally managing breast cancer-related lymphedema. J Person Med. 2014;4:424–47.CrossRef
10.
Perdomo M, Levenhagen K, Ryans K. Breast Cancer EDGE Task Force Outcomes: Assessment measures of secondary lymphedema in breast cancer survivors. Rehabil Oncol. 2014;32:22–35.
11.
NLNMA, C. Supplement to the NLN position breast cancer screening: screening and early detection of breast cancer-related lymphedema. The Imperative. National Lymphedema Network, 2012.
12.
Commitee, NLNMA. Supplement to the NLN position breast cancer screening: screening and early detection of breast cancer -related lymphedema. The Imperative, 2012, National Lymphedema Network.
13.
Armer JM. The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest. 2005;23:76–83.PubMedCrossRef
14.
Olszewski WL (1991) Volumetry of limbs, in Pathophysiology, Diagnosis, and Treatment. CRC Press, Boston pp. 444–51.
15.
16.
Armer JM, Stewart BR. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months. Lymphology. 2010;43:118–27.PubMedPubMedCentral
17.
Taylor R, et al. Reliability and validity of arm volume measurements for assessment of lymphedema. Phys Ther. 2006;86:205–14.PubMed
18.
Stout Gergich NL, et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer. 2008;112:2809–19.PubMedCrossRef
19.
Johansson K, Branje E. Arm lymphoedema in a cohort of breast cancer survivors 10 years after diagnosis. Acta Oncol. 2010;49:166–73.PubMedCrossRef
20.
Bar Ad V, et al. Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2010;76:85–90.CrossRef
21.
Torres Lacomba M, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010;340:b5396.PubMedPubMedCentralCrossRef
22.
Lahtinen T, et al. Experimental and analytical comparisons of tissue dielectric constant (TDC) and bioimpedance spectroscopy (BIS) in assessment of early arm lymphedema in breast cancer patients after axillary surgery and radiotherapy. Lymphatic Res Biol. 2015;13:176–85.CrossRef
23.
Stout NL, et al. Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. Phys Ther. 2012;92:152–63.PubMedCrossRef
24.
25.
26.
Kilbreath SL, et al. Transient swelling versus lymphoedema in the first year following surgery for breast cancer. Support Care Cancer. 2013;21:2207–15.PubMedCrossRef
27.
Laidley A, Anglin B. The impact of L-Dex((R)) measurements in assessing breast cancer-related lymphedema as part of routine clinical practice. Frontiers Oncol. 2016;6:192.CrossRef
28.
Specht MC, et al. Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression? Breast Cancer Res Treat. 2013;140:485–94.PubMedPubMedCentralCrossRef
29.
30.
Armer JM, et al. Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res. 2003;52:370–9.PubMedCrossRef
31.
Teo I, et al. Examining pain, body image, and depressive symptoms in patients with lymphedema secondary to breast cancer. Psycho-oncology. 2015;24:1377–83.PubMedCrossRef
32.
Sackey H, et al. Self-perceived, but not objective lymphoedema is associated with decreased long-term health-related quality of life after breast cancer surgery. Eur J Surg Oncol. 2015;41:577–84.PubMedCrossRef
33.
Bulley C, et al. Comparison of breast cancer-related lymphedema (upper limb swelling) prevalence estimated using objective and subjective criteria and relationship with quality of life. BioMed Res Int. 2013;2013:807569.PubMedPubMedCentralCrossRef
34.
35.
Ridner SH, Dietrich MS, Kidd N. Breast cancer treatment-related lymphedema self-care: education, practices, symptoms, and quality of life. Support Care Cancer. 2011;19:631–7.PubMedCrossRef
36.
Hayes SC, et al. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;118(8 Suppl):2237–49.PubMedCrossRef
37.
Pusic AL, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Survivorship Res Pract. 2013;7:83–92.CrossRef
38.
Brach M, et al. ICF core sets for breast cancer. J Rehabil Med. 2004; 36(44 Suppl):121–127.CrossRef
39.
Devoogdt N, et al. Lymphoedema functioning, disability, and health questionnaire (Lymph-ICF): reliability and validity. Phys Ther. 2011;91:944–57.PubMedCrossRef
40.
41.
Bulley C, et al. A morbidity screening tool for identifying fatigue, pain, upper limb dysfunction, and lymphedema after breast cancer treatment: a validity study. Eur J Oncol Nurs. 2014;18:218–27.PubMedCrossRef
42.
43.
44.
Blaney JM, et al. Prospective surveillance of breast cancer-related lymphoedema in the first-year post-surgery: feasibility and comparison of screening measures. Support Care Cancer. 2015;23:1549–59.PubMedCrossRef
45.
Czerniec SA, et al. Assessment of breast cancer-related arm lymphedema: comparison of physical measurement methods and self-report. Cancer Invest. 2010;28:54–62.PubMedCrossRef
46.
Gartner R, et al. Self-reported arm-lymphedema and functional impairment after breast cancer treatment: a nationwide study of prevalence and associated factors. Breast. 2010;19:506–15.PubMedCrossRef
47.
Coster S, Poole K, Fallowfield LJ. The validation of a quality-of-life scale to assess the impact of arm morbidity in breast cancer patients postoperatively. Breast Cancer Res Treat. 2001;68:273–82.PubMedCrossRef
48.
Keeley V, C.S., Locke J, Viegas D. A quality-of-life measure for limb lymphedema (LYMQOL). J Lymphoedem. 2010;5:26–37.
49.
Weiss J, Daniel T. Validation of the Lymphedema Life Impact Scale (Llis): a condition-specific measurement tool for persons with lymphedema. Lymphology. 2015;48:128–38.PubMed
50.
Ozcinar B, et al. Breast cancer-related lymphedema in patients with different locoregional treatments. Breast. 2012;21:361–5.PubMedCrossRef
51.
Nesvold IL, et al. Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. Acta Oncol. 2008;47:835–42.PubMedCrossRef
52.
Ashikaga T, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102:111–8.PubMedPubMedCentralCrossRef
53.
Wernicke AG, et al. A 10-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance. Breast Cancer Res. Treat. 2011;125:893–902.PubMedCrossRef
54.
Swaroop MN, et al. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat. 2015;151:393–403.PubMedPubMedCentral
55.
Viera RA, de Souza JL, et al. Risk factors for arm lymphedema in a cohort of breast cancer patients followed for 10 years. Breast Cancer Basel. 2016;11:45–50.
56.
Vicini F, et al. Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic. Clin Breast Cancer. 2012;12:133–7.PubMedCrossRef
57.
Coen JJ, et al. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55:1209–15.PubMedCrossRef
58.
Hayes SB, et al. Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation? Int J Radiat Oncol Biol Phys. 2008;72:1449–55.PubMedCrossRef
59.
Kim M, et al. Identification of prognostic risk factors for transient and persistent lymphedema after multimodal treatment for breast cancer. Cancer Res Treat. 2016;48:1330–7.PubMedPubMedCentralCrossRef
60.
Kilbreath SL, et al. Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast. 2016;28:29–36.PubMedCrossRef
61.
Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 noninferiority trial. Lancet Oncol. 2014;15:1303–10.PubMedPubMedCentralCrossRef
62.
Cariati M, et al. Adjuvant taxanes and the development of breast cancer-related arm lymphoedema. Br J Surg. 2015;102:1071–8.PubMedCrossRef
63.
64.
65.
Wetzig N, et al, Sentinel-lymph-node-based management or routine axillary clearance? Five-year outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: assessment and incidence of true lymphedema. Ann Surg Oncol. 2017;24:1064–70.PubMedCrossRef
66.
Rebegea L, et al. The incidence and risk factors for occurrence of arm lymphedema after treatment of breast cancer. Chirurgia. 2015;110:33–7.PubMed
67.
Ridner SH, Dietrich MS. Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. Oncol Nurs Forum. 2008;35:57–63.PubMedCrossRef
68.
Deutsch M, et al. The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys. 2008;70:1020–4.PubMedCrossRef
69.
70.
McLaughlin SA, et al. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 2012; 216:380–389.PubMedCrossRef
71.
72.
DiSipio T, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500–15.PubMedCrossRef
73.
Helyer LK, et al. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 2010;16:48–54.PubMedCrossRef
74.
Boccardo FM, et al. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology. 2009;42:1–9.PubMed
75.
76.
77.
Lu SR, et al. Role of physiotherapy and patient education in lymphedema control following breast cancer surgery. Therapeut Clin Risk Manage. 2015;11:319–27.
78.
Basen-Enquist K, T.C., Rosenblum C, Smith MA, Shinn EH, Greisinger A. Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors. Patient Educ Couns. 2016;64:225–34.CrossRef
79.
Szuba A, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002;16:1985–7.PubMed
80.
81.
Jin DP, et al. Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization. Lymphat Res Biol. 2009;7:47–57.PubMedCrossRef
82.
Tammela T, et al. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med. 2007;13:1458–66.PubMedCrossRef
83.
Norrmen C, et al. Biological basis of therapeutic lymphangiogenesis. Circulation. 2011;123:1335–51.PubMedCrossRef
84.
Saaristo A, et al. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J. 2004;18:1707–9.PubMed
85.
Goldman J, et al. Overexpression of VEGF-C causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin. Circ Res. 2005;96:1193–9.PubMedCrossRef
86.
Qi S, Pan J. Cell-based therapy for therapeutic lymphangiogenesis. Stem Cells Develop. 2015;24:271–83.CrossRef
87.
Yan A, et al. Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-beta1 inhibition. Future Oncol. 2011;7:1457–73.PubMedPubMedCentralCrossRef
88.
Shimizu Y, Shibata S.R, Shintani S, Ishii M, Murohara T. Therapeutic lymphangiogenesis with implantation of adipose-derived regenerative cells. J Am Heart Assoc. 2012; 1:e000877.PubMedPubMedCentralCrossRef
89.
Ackermann M, Senaldi C, Kalbermatten D, Konerding M, Raffoul W, Erba P, Impact of platelet rich plasma and adipose stem cells on lymphangiogenesis in a murine tail lymphedema model. Microvasc Res. 2015;102:78–85.PubMedCrossRef
90.
Chen HC, et al. Lymph node transfer for the treatment of obstructive lymphoedema in the canine model. Br J Plast Surg. 1990;43:578–86.PubMedCrossRef
91.
92.
Lahteenvuo M, et al. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation. 2011;123:613–20.PubMedCrossRef
93.
Hadamitzky C, et al. Aligned nanofibrillar collagen scaffolds: guiding lymphangiogenesis for treatment of acquired lymphedema. Biomaterials. 2016;102:259–67.PubMedPubMedCentralCrossRef
94.
Huang NF, et al. The modulation of endothelial cell morphology, function, and survival using anisotropic nanofibrillar collagen scaffolds. Biomaterials. 2013;34:4038–47.PubMedPubMedCentralCrossRef
95.
Badger C, et al. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database System Rev. 2004; 2:CD003140.
96.
Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol. 2008;52:799–806.PubMedCrossRef
97.
98.
99.
Nakamura K, et al. Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. PloS One. 2009;4:e8380.PubMedPubMedCentralCrossRef
100.
Tian W, et al. Leukotriene B4 antagonism ameliorates experimental lymphedema. Sci Translat Med. 2017; 9(389):eaal3920.CrossRef
101.
102.
Olson JA Jr, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol. 2008;26:3530–5.PubMedCrossRef
103.
Wilke LG, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500.PubMedCrossRef
104.
Lucci A, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–63.PubMedCrossRef
105.
Galimberti V, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305.PubMedPubMedCentralCrossRef
106.
Choi YH, Seo KS. Correlation among bioimpedance analysis, sonographic and circumferential measurement in assessment of breast cancer-related arm lymphedema. Lymphology. 2014;47:123–33.PubMed
107.
Devoogdt N, et al. Postoperative evolution of thickness and echogenicity of cutis and subcutis of patients with and without breast cancer-related lymphedema. Lymphat Res Biol. 2014;12:23–31.PubMedCrossRef
108.
109.
Johnson KC, et al. Ultrasound and clinical measures for lymphedema. Lymphat Res Biol. 2016;14:8–17.PubMedCrossRef
110.
Mayrovitz HN, Weingrad DN, Lopez L. Patterns of temporal changes in tissue dielectric constant as indices of localized skin water changes in women treated for breast cancer: a pilot study. Lymphat Res Biol. 2015;13:20–32.PubMedCrossRef
111.
Mellor RH, et al. Dual-frequency ultrasound examination of skin and subcutis thickness in breast cancer-related lymphedema. Breast J. 2004;10:496–503.PubMedCrossRef
112.
Metadata
Title
Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel
Part 1: Definitions, Assessments, Education, and Future Directions
Authors
Sarah A. McLaughlin, MD
Alicia C. Staley, MBA, MS, BS
Frank Vicini, MD, FACR, FABS
Paul Thiruchelvam, BSc, MD, PhD, FRCS
Nancy A. Hutchison, MD, CLT-LANA
Jane Mendez, MD
Fiona MacNeill, FRCS, MD, FEBS
Stanley G. Rockson, MD
Sarah M. DeSnyder, MD
Suzanne Klimberg, MD, PhD
Michael Alatriste, LMT, CLT
Francesco Boccardo, MD, PhD, FACS
Mark L. Smith, MD, FACS
Sheldon M. Feldman, MD, FACS
Publication date
01-10-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 10/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-5982-4

Other articles of this Issue 10/2017

Annals of Surgical Oncology 10/2017 Go to the issue

Breast Oncology

Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database

Breast Oncology

Prospective Study Comparing Surgeons’ Pain and Fatigue Associated with Nipple-Sparing versus Skin-Sparing Mastectomy

Breast Oncology

Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members

Breast Oncology

A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease

Breast Oncology

Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?

Breast Oncology

A Single Institution Retrospective Comparison Study of Locoregional Recurrence After Accelerated Partial Breast Irradiation Using External Beam Fractionation Compared with Whole Breast Irradiation with 8 Years of Follow-Up